Delving into the Latest Updates on Santen Pharmaceutical (China) Co. Ltd. with Synapse

Overview

Tags

Eye Diseases

Immune System Diseases

Small molecule drug

Non-degrading molecular glue

Polymer

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	3
Infectious Diseases	2
Nervous System Diseases	1
Hemic and Lymphatic Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	2
Non-degrading molecular glue	1
Polymer	1
Synthetic peptide	1

Top 5 Target	Count

CaN(Calcineurin)	1
H1 receptor(Histamine H1 receptor)	1
PTGFR x β-adrenoceptors	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

3

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tafluprost/Timolol Maleate ( PTGFR x β-adrenoceptors )	Ocular Hypertension More	Approved
Cyclosporine ( CaN )	Conjunctivitis, Allergic More	Approved
Sodium Hyaluronate	Corneal Injuries More	Approved
Epinastine Hydrochloride ( H1 receptor )	Conjunctivitis, Allergic More	Phase 3